Vysis
Downers Grove
About Vysis
Vysis develops, commercializes and markets clinical products that provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The Company has assembled a management team experienced in developing,commercializing and marketing DNA based diagnostic products and associated genetic workstations. The Company was the first to obtain Food and Drug Administration ("FDA") clearance for a genomic product using fluorescence INSITU hybridization ("FISH"). Vysis currently markets four FDA cleared clinical products in addition to distributing over 240 research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 28 countries. It has an installed base of over 320 proprietary genetic workstations at 224 laboratories in 18 countries. The Company has a pipeline of nine clinical products under development and an expanding list of clinical product leads based upon its collaborations with leading medical research institutions, which include the University of California, San Francisco, the Mayo Clinic, St. Jude Children's Research Hospital, the University of Chicago and the Reproductive Genetics Institute.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Website: vysis.com
Canonical: https://fsome.com/organization/vysis-2290120 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.